This invention relates to methods of treating cancer with platanoside and/or isomers thereof or pharmaceutically acceptable salts thereof, particularly treatment of a pancreatic, liver or brain cancer. This invention further relates to methods of treating cancer with platanoside and/or isomers thereof, produced from Ephedra foeminea.

The present disclosure provides a method for extracting and separating flavonoids from Lindera aggregata leaves. The method includes: mixing Lindera aggregata leaves with an adsorbent, conducting elution with a matrix solid-phase dispersion (MSPD) extraction method, followed by concentration to obtain a Lindera aggregata leaf extract; conducting primary separation and secondary separation on the Lindera aggregata leaf extract by high-speed counter-current liquid chromatography (HSCCC), to separate quercetin-3-O-β-D-arabinofuranoside, a mixture of quercetin-3-O-β-D-glucoside and quercetin-5-O-β-D-glucoside, quercetin-3-O-rhamnopyranoside, and kaempferol-7-O-α-L-rhamnopyranoside; where a second solvent system used in the secondary separation includes ethyl acetate, n-butanol, an addictive and water, and the addictive includes cyclodextrin. The method has a short separation period, high separation efficiency, and less impurities during purification and separation of the flavonoids from the Lindera aggregata leaves.

The present disclosure provides a method for extracting and separating flavonoids from Lindera aggregata leaves. The method includes: mixing Lindera aggregata leaves with an adsorbent, conducting elution with a matrix solid-phase dispersion (MSPD) extraction method, followed by concentration to obtain a Lindera aggregata leaf extract; conducting primary separation and secondary separation on the Lindera aggregata leaf extract by high-speed counter-current liquid chromatography (HSCCC), to separate quercetin-3-O-β-D-arabinofuranoside, a mixture of quercetin-3-O-β-D-glucoside and quercetin-5-O-β-D-glucoside, quercetin-3-O-rhamnopyranoside, and kaempferol-7-O-α-L-rhamnopyranoside; where a second solvent system used in the secondary separation includes ethyl acetate, n-butanol, an addictive and water, and the addictive includes cyclodextrin. The method has a short separation period, high separation efficiency, and less impurities during purification and separation of the flavonoids from the Lindera aggregata leaves.

The present invention relates to compounds according to general formula (I) with enhanced absorption of UV-B irradiation. The present invention also relates to an UV-B tolerant plant and a method for enhanced production of compounds according to general formula (I) in a plant or plant cell. Furthermore, the invention relates to a nucleic acid sequence SEQ-ID No. 1 encoding FPT2 catalyzing the production of compounds according to general formula (I). The invention further relates to compositions comprising compounds according to general formula (I). Furthermore, the invention relates to a method of conferring UV-B tolerance to a plant as well as an UV-B tolerant plant comprising the nucleic acid sequence SEQ-ID No. 1 encoding FPT2 catalyzing the production of compounds according to general formula (I).

The present invention relates to compounds according to general formula (I) with enhanced absorption of UV-B irradiation. The present invention also relates to an UV-B tolerant plant and a method for enhanced production of compounds according to general formula (I) in a plant or plant cell. Furthermore, the invention relates to a nucleic acid sequence SEQ-ID No. 1 encoding FPT2 catalyzing the production of compounds according to general formula (I). The invention further relates to compositions comprising compounds according to general formula (I). Furthermore, the invention relates to a method of conferring UV-B tolerance to a plant as well as an UV-B tolerant plant comprising the nucleic acid sequence SEQ-ID No. 1 encoding FPT2 catalyzing the production of compounds according to general formula (I).

The present application provides, in some aspects, methods of treating cancers, such as homologous recombination (HR)-deficient cancers. In some embodiments, the disclosure provides a method for treating cancer by administering to a subject a compound of Formula (I):(I), or a pharmaceutically acceptable salt thereof. ##STR00001##

The present application provides, in some aspects, methods of treating cancers, such as homologous recombination (HR)-deficient cancers. In some embodiments, the disclosure provides a method for treating cancer by administering to a subject a compound of Formula (I):(I), or a pharmaceutically acceptable salt thereof. ##STR00001##

The present disclosure discloses scutellarin amide derivatives and preparation methods and uses thereof, which belongs to the field of natural drugs and medicinal chemistry. The scutellarin amide derivatives according to the present disclosure and pharmaceutically acceptable salts thereof have a structure as shown in the following general formula I:

##STR00001##

scutellarin derivatives, which are prepared by amidation at the glycosylcarboxyl site, can be used in the manufacture of anti-tumor drugs, which have a good effect against tumor cell proliferation.

The present disclosure discloses scutellarin amide derivatives and preparation methods and uses thereof, which belongs to the field of natural drugs and medicinal chemistry. The scutellarin amide derivatives according to the present disclosure and pharmaceutically acceptable salts thereof have a structure as shown in the following general formula I:

##STR00001##

scutellarin derivatives, which are prepared by amidation at the glycosylcarboxyl site, can be used in the manufacture of anti-tumor drugs, which have a good effect against tumor cell proliferation.

Process for the preparation of diosmin.